Foresight: Eye-Net Funding Changed the Value Split
Eye-Net’s two 2025 funding rounds extended Foresight’s cash runway, but they also sold 10.64% of the asset, layered in anti-dilution protection, and created a large warrant overhang at the listed parent. The real question is no longer only what Eye-Net is worth, but how much of that value still belongs to common shareholders at Foresight.
The main article argued that Foresight’s commercialization progress still does not justify the dilution. This follow-up isolates the structural layer underneath that conclusion: Eye-Net’s two 2025 funding rounds did not just buy time. They changed how future value is split between Foresight shareholders, minority investors inside Eye-Net, and warrant holders at the listed parent.
If you only look at the round valuations, the move can look clean. Eye-Net raised money in March 2025 at a $45 million pre-money valuation, then again in December 2025 at a $55 million pre-money valuation. On that reading, Foresight seems to have marked up its main asset without giving up too much of it. That is incomplete. In practice, 2025 added three new layers around the same asset: dilution in Eye-Net ownership, anti-dilution protection at the subsidiary, and parent-level warrants at Foresight. The key question is no longer just what Eye-Net is worth on paper, but how much of that value remains with Foresight’s ordinary shareholders after all those layers are accounted for.
The Rounds Bought Time, but Time Was Not Free
On liquidity, the two Eye-Net rounds clearly mattered. Foresight ended 2025 with $6.289 million of cash, restricted cash, and similar balances after using $10.453 million in operating cash flow. Total financing cash flow for the year was $9.476 million, and $5.311 million of that net amount came from the two Eye-Net investments. In other words, 56% of 2025 financing came from selling equity in the subsidiary, not just from issuing Foresight ADSs.
The consolidated arithmetic shows just how dependent the runway became on Eye-Net capital. If the $5.311 million net proceeds from the two Eye-Net rounds are stripped out, year-end cash would have fallen to roughly $0.978 million instead of $6.289 million. So when management says existing cash should fund operations through August 2026, that statement rests heavily on having sold part of Eye-Net to outside investors.
That distinction matters because two statements that sound similar are not the same. The company bought time, but it did not buy it for free. It paid for that time by redistributing rights around its main asset, not only by issuing ordinary equity at the parent.
100% Became 89.36%, and That Was Only the First Step
In March 2025, Eye-Net raised $2.75 million gross and Foresight’s stake fell from 100% to 94.2%. In December 2025, Eye-Net raised another $3 million gross and Foresight’s stake fell again, from 94.2% to 89.36%. Put simply, Foresight shareholders no longer own all of Eye-Net’s upside. They own 89.36% of it.
| Round | Pre-money valuation | Gross proceeds | Foresight stake after the round | What came with it |
|---|---|---|---|---|
| March 2025 | $45 million | $2.75 million | 94.2% | Anti-dilution protection at Eye-Net, Series A and Series B warrants at Foresight |
| December 2025 | $55 million | $3 million | 89.36% | Anti-dilution protection at Eye-Net, Series A and Series C warrants, plus a repricing of Series B for repeat investors |
This is where investors should avoid the post-money illusion. Yes, the December round was done at a higher valuation, so in a rough look-through calculation Foresight’s 89.36% stake still implies about $51.8 million of value based on Eye-Net’s $58 million post-money valuation. But that is no longer the same asset Foresight once owned outright, and it is not clean value that automatically accrues to common shareholders. Once minority investors are inside the subsidiary, the question shifts from what Eye-Net is worth on paper to how much of that value actually remains with Foresight after all the contractual layers sitting around it.
A Higher Valuation Still Created More Dilution
The most important and easiest-to-miss point sits inside the protection mechanics. In both rounds, Eye-Net granted investors one-year anti-dilution protection if it completed an equity financing above $1 million at a lower price, subject to a $30 million pre-money floor. That means year-end 2025 leaves Foresight with an 89.36% stake in Eye-Net, but with two live reset clauses still sitting underneath it.
That matters for two reasons. First, 89.36% is not a finish line. If Eye-Net needs another weaker round, ordinary shareholders can be diluted again at the subsidiary before any new parent-level dilution is even considered. Second, the higher December valuation did not prevent pain at the listed parent. It actually came with new concessions there.
In December 2025, for March investors who participated again, the exercise price of the Series B warrants was reduced from $18.1125 per ADS to $8.1375 per ADS. That is a cut of about 55.1%. It is one of the sharpest clues to the new value split: Eye-Net’s valuation can move up in the next round while the parent still improves the economics it gives to selected investors through cheaper Foresight warrants.
The company measured the incremental fair value of that repricing at $164,000 and recognized it as an equity issuance cost. That is not a minor accounting footnote. It is an admission that the parent did not only sell part of Eye-Net. It also sweetened the rights granted to certain investors above the head of ordinary shareholders.
The Parent-Level Warrants Are the Easiest Layer to Miss
Part of the dilution already happened in 2025. The statement of changes in equity shows that 31.816 million ordinary shares were issued through warrant exercises during the year, and that number exactly matches the Series A exercises disclosed in the note. But the story does not stop with what was already exercised.
As of year-end 2025, and based on the issuance caps disclosed in the note, a very large warrant layer was still outstanding:
- Up to 3.814 million ordinary shares remained under the March Series A warrants.
- Up to 54.845 million ordinary shares remained under the December Series A warrants.
- Series B still represented 12.834 million ordinary shares.
- Series C still represented 31.106 million ordinary shares.
That means the disclosed year-end ceiling still pointed to roughly 102.6 million additional ordinary shares. That is equivalent to about 73% of the 140.634 million shares issued and outstanding at the end of 2025.
This is exactly where investors tend to make the wrong mental shortcut. They see a financing at the subsidiary and think only about dilution at the subsidiary. At Foresight, 2025 also created a separate dilution stack at the public wrapper. So even if Eye-Net keeps moving to higher round valuations, the ownership of that upside per existing Foresight share can still be diluted through an entirely different channel.
The Balance Sheet Shows That Valuation and Equity Are Not the Same
Another way to understand the new value split is to look at the balance sheet and the statement of changes in equity rather than the round valuations. At the end of 2025, consolidated equity stood at $5.111 million, down from $6.730 million a year earlier. Equity attributable to Foresight shareholders itself rose only from $6.066 million to $6.233 million, a gain of just $167,000. At the same time, non-controlling interest swung from a positive $664,000 to negative $1.122 million.
| Equity line | End of 2024 | End of 2025 | Change |
|---|---|---|---|
| Equity attributable to Foresight shareholders | 6.066 | 6.233 | 0.167 |
| Non-controlling interest | 0.664 | -1.122 | -1.786 |
| Total consolidated equity | 6.730 | 5.111 | -1.619 |
There is a sharp analytical message in that table. The market can look at Eye-Net through $45 million and then $55 million pre-money valuations, while the consolidated balance sheet still tells a much narrower story. The group burned through most of the fresh capital in operating losses, and minority interest did not end the year as a clean positive equity layer. It ended up negative.
The most interesting line in the statement of changes in equity reinforces the same point. “Issuance of shares in subsidiary” added $2.508 million to additional paid-in capital attributable to Foresight shareholders, but reduced non-controlling interest by $1.716 million, so the total increase in consolidated equity was only $792,000. That is the difference between accounting value and accessible value: a financing round can create an impressive price tag for the asset, but it does not mean the group has suddenly built a large, clean equity cushion.
In a simple look-through reading, the negative non-controlling interest balance also implies that Eye-Net’s book equity was still negative at year-end 2025. That matters because it separates round valuation based on future commercialization potential from balance-sheet value that has already been earned and retained inside the business.
What Still Belongs to the Common Shareholder
Three conclusions follow.
Control remains. Foresight still owns 89.36% of Eye-Net. If Eye-Net turns its Europe and Japan paths into real commercial revenue, Foresight still sits on most of the upside.
Part of the upside has already been sold. Foresight no longer owns 100% of the asset, and the two anti-dilution layers mean that percentage can still erode if another weaker financing becomes necessary.
A parent-level dilution layer remains in place. Even if Eye-Net succeeds, the way value will be split between existing Foresight shares, parent warrant holders, and Eye-Net minority investors now looks very different from what it did at the start of 2025.
So the next test is not whether Eye-Net was tagged at $45 million or $55 million. The real test is whether commercialization advances before the company needs to divide the pie again, and whether the next round, if there is one, can be done on terms that do not trigger the protection mechanics or further worsen dilution at Foresight.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.